Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
== Terminology == The name used until 2026, polycystic ovary syndrome (PCOS), derived from a typical finding on medical images called "polycystic ovary morphology". A polycystic ovary has an abnormally large number of developing follicles, looking like many small cysts. There were various objections to the name polycystic ovary syndrome: the "cysts" are not truly cysts, but arrested follicles. Having many follicles in the ovaries is also not unique to PMOS, and is often seen in women without PMOS, particularly adolescents. Furthermore, the name implied that PMOS is a gynecological condition only, rather than a metabolic and endocrine condition. Other previous names for PMOS were Stein–Leventhal syndrome and polycystic ovary disease. Suggested names included hyperandrogenic (chronic) anovulation, estrogenic ovulatory dysfunction or functional female hyperandrogenism. For specific subgroups, suggested names included multi-follicular ovarian disorder for those with polycystic ovary morphology, and metabolic hyperandrogenic syndrome for those meeting the NIH PMOS criteria. Following discussions among clinicians and people with PCOS, a majority of whom were in favour of renaming the condition, a survey was launched to find a new name. In 2026, an article by Helena Teede and others in The Lancet described the "multistep global consensus process" through which clinicians agreed to rename the condition "polyendocrine metabolic ovarian syndrome" (PMOS).
Prolactin (PRL), also known as lactotropin and mammotropin, is a protein best known for its role in enabling mammals to produce milk. It is influential in over 300 separate processes in various vertebrates, including humans. Prolactin is secreted from the pituitary gland and plays an essential role in metabolism, regulation of the immune system and pancreatic development. Discovered in non-human animals around 1930 by Oscar Riddle and confirmed in humans in 1970 by Henry Friesen, prolactin is a peptide hormone, encoded by the PRL gene. In mammals, prolactin is associated with milk production; in fish it is thought to be related to the control of water and salt balance. Prolactin also acts in a cytokine-like manner and as an important regulator of the immune system. It has important cell cycle-related functions as a growth-, differentiating- and anti-apoptotic factor. As a growth factor, binding to cytokine-like receptors, it influences hematopoiesis and angiogenesis and is involved in the regulation of blood clotting through several pathways. The hormone acts in endocrine, autocrine, and paracrine manners through the prolactin receptor and numerous cytokine receptors. Pituitary prolactin secretion is regulated by endocrine neurons in the hypothalamus. The most important of these are the neurosecretory tuberoinfundibulum (TIDA) neurons of the arcuate nucleus that secrete dopamine (a.k.a. prolactin inhibitory hormone) to act on the D2 receptors of lactotrophs, causing inhibition of prolactin secretion.
Pheromone Endorphins Anaphrodisiac Date rape drug Entactogen Food and sexuality Fork Me, Spoon Me, 2006 book Hypersexuality Hypoactive sexual desire disorder List of investigational sexual dysfunction drugs Love potion Phytoestrogen Phytoandrogen Androgens Estrogens Viagra Vyleesi
=== Croatian === The longest known word in Croatian is prijestolonasljednikovičičinima, meaning "to those who belong to the throne successor's little wife." The 30-letter word ("lj" is considered as one letter in Croatian) is the dative case of prijestolonasljednikovičica "the throne successor's little wife" which is the diminutive of prijestolonasljednikovica "the throne successor's wife."
Sources: en.wikipedia.org
Theanine , also known as L-γ-glutamylethylamide, N5-ethyl-L-glutamine, or γ-glutamylethylamide, is a bioactive, non-proteinogenic amino acid similar to the proteinogenic amino acids glutamic acid and L-glutamine. It is produced by certain plants such as the tea plant (Camellia sinensis), and by some fungi. Theanine was discovered in 1949 as a constituent of green tea and was isolated in 1950 from gyokuro tea leaves. Theanine constitutes about 1–2% of the dry weight of green tea leaves. Theanine is sold as a dietary supplement. It is packaged in gelatin capsules, tablets, and as a powder, and may be an ingredient in branded supplements with caffeine. It is also used as an ingredient in food and beverages. Japan approved its unlimited use in all foods (including chocolates, soft drinks, and herb teas) except infant food in 1964, and the US Food and Drug Administration has considered it safe at doses up to 250 milligrams (mg) per serving since 2007. In 2011, the European Food Safety Authority found there was insufficient evidence for a causal relationship between theanine consumption and improved cognitive function, alleviation of psychological stress, maintenance of normal sleep, or reduction of menstrual discomfort. A 2025 review found that theanine has been poorly studied to date, having inconsistent research quality and unreliable clinical trials.
== History == Reslizumab was initially developed by Chuan-Chu Chou at Schering-Plough and was previously known as SCH-55700. In 1993, Chou and his group at Schering-Plough were granted the patent for the design, cloning and expression of the reslizumab drug. Ception Therapeutics acquired the drug and continued its development under the name CTx55700. In 2010, Ception Therapeutics was acquired by Cephalon for $250 million and the drug continued under development under the codename CEP-38072. In 2011, Teva Pharmaceuticals acquired Cephalon for $6.8 billion and continued the development of reslizumab.
According to US State Department Spokesperson, Jen Psaki : "US law exempts foreign government officials, including heads of state and heads of government from certain potential inadmissibility grounds". The visa refusal came after some Indian-American groups and human rights organizations with political view campaigned against Modi, including the Coalition Against Genocide. On June 11, 2014, Robert Blackwill, the former Coordinator for Strategic Planning and Deputy US National Security Advisor during the presidency of George W. Bush, spoke at length about India–U.S. relations and said : "Mr Modi is a determined leader. He is candid and frank. I also worked with him during the Gujarat earthquake when I was posted as (the US) ambassador to India. ... It was mistake by the current Obama administration to delay engagement with Mr Modi. I do not know why they did so but definitely, this did not help in building relationship. ... The old formula and stereotypes will not work if the US administration wants to engage with Mr Modi. The Indian prime minister is candid, direct and smart. He speaks his mind. The US administration also has to engage in candid conversation when Mr Modi meets President Obama later this year. They have to do something innovative to engage with him." Nicholas Burns, former U.S.
=== Rate of flow === Rate of blood flow varies greatly between different organs. Liver has the most abundant blood supply with an approximate flow of 1350 ml/min. Kidney and brain are the second and the third most supplied organs, with 1100 ml/min and ~700 ml/min, respectively. Relative rates of blood flow per 100 g of tissue are different, with kidney, adrenal gland and thyroid being the first, second and third most supplied tissues, respectively.
The primary purpose of the electrocardiogram is to detect ischemia or acute coronary injury in broad, symptomatic emergency department populations. A serial ECG may be used to follow rapid changes in time. The standard 12 lead ECG does not directly examine the right ventricle, and is relatively poor at examining the posterior basal and lateral walls of the left ventricle. In particular, acute myocardial infarction in the distribution of the circumflex artery is likely to produce a nondiagnostic ECG. The use of additional ECG leads like right-sided leads V3R and V4R and posterior leads V7, V8, and V9 may improve sensitivity for right ventricular and posterior myocardial infarction. The 12 lead ECG is used to classify patients into one of three groups:
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.